DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Emcure Pharmaceuticals Limited — Investor Presentation

NSE 1 hr ago·3 Nov 2026, 8:34 am

Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited has announced the schedule for its upcoming investor presentation. This event is a standard corporate disclosure where the company management outlines its strategic roadmap, financial performance, and future outlook to the market.

For investors, such presentations are crucial as they provide transparency into management's plans and potential growth drivers. It offers a direct look at the company's vision, helping retail investors assess the firm's trajectory and compare it against market expectations.

Investors should watch for updates on product pipelines, expansion strategies, and financial targets. Monitoring the Q&A session and management commentary will be key to understanding how Emcure plans to navigate the competitive pharmaceutical landscape.